Share Purchase Options (Details) |
9 Months Ended |
|---|---|
|
May 31, 2019
$ / shares
shares
| |
| Options Outstanding | 9,808,333 |
| Options Exercisable | 4,858,333 |
| Weighted average remaining contractual life, Options Outstanding | 8 years 10 months 25 days |
| Weighted average remaining contractual life, Options Exercisable | 8 years 10 months 25 days |
| Weighted average exercise price, Options Outstanding | $ / shares | $ 1.20 |
| Weighted average exercise price, Options Exercisable | $ / shares | 1.41 |
| February 1, 2026 [Member] | |
| Exercise Price | $ / shares | $ 5.85 |
| Options Outstanding | 33,333 |
| Options Exercisable | 33,333 |
| November 30, 2027 [Member] | |
| Exercise Price | $ / shares | $ 2.27 |
| Options Outstanding | 1,425,000 |
| Options Exercisable | 1,425,000 |
| June 5, 2028 [Member] | |
| Exercise Price | $ / shares | $ 1.00 |
| Options Outstanding | 8,350,000 |
| Options Exercisable | 3,400,000 |
| X | ||||||||||
- Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of options outstanding, including both vested and non-vested options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|